HAEMALOGIX

Haemalogix focuses on the development and commercialization of novel immuno-oncology and immune-therapies.HaemaLogiX acquired the business and assets of Immune System Therapeutics Ltd and is embarking on a program of several inter-related projects that will validate antigen targets and products. Two novel drug targets - Kappa Myeloma Antigen (KMA) and Lambda Myeloma Antigen (LMA), have been identified on the surface of human blood cancer and autoimmune cells. These targets are highly specific... to abnormal B-cells and have been identified in blood cancers such as multiple myeloma (MM), lymphoma and Waldenstroms macroglobulinemia. Our program will rationally review and pursue opportunities that will deliver a positive proof of the clinical and financial viability of our assets. These opportunities include: validation of antibodies and CAR-T cells; proof of concept for both Kappa and Lambda antigens; and a good understanding of their clinical utility in treating the selected patient populations In pursuing these projects we wish to deliver significant and risk mitigated medium term returns to our investors.More